Annovis Bio (ANVS) Competitors $2.21 -0.06 (-2.64%) Closing price 10/9/2025 03:59 PM EasternExtended Trading$2.18 -0.03 (-1.36%) As of 05:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANVS vs. ALXO, CYBN, CRBP, BTMD, NKTX, SAVA, CLYM, AVTX, GLSI, and CRDFShould you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include ALX Oncology (ALXO), Cybin (CYBN), Corbus Pharmaceuticals (CRBP), biote (BTMD), Nkarta (NKTX), Cassava Sciences (SAVA), Climb Bio (CLYM), Avalo Therapeutics (AVTX), Greenwich LifeSciences (GLSI), and Cardiff Oncology (CRDF). These companies are all part of the "pharmaceutical products" industry. Annovis Bio vs. Its Competitors ALX Oncology Cybin Corbus Pharmaceuticals biote Nkarta Cassava Sciences Climb Bio Avalo Therapeutics Greenwich LifeSciences Cardiff Oncology ALX Oncology (NASDAQ:ALXO) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends. Does the media prefer ALXO or ANVS? In the previous week, ALX Oncology had 1 more articles in the media than Annovis Bio. MarketBeat recorded 6 mentions for ALX Oncology and 5 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.00 beat ALX Oncology's score of -0.12 indicating that Annovis Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Annovis Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in ALXO or ANVS? 98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, ALXO or ANVS? ALX Oncology has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Do analysts prefer ALXO or ANVS? ALX Oncology presently has a consensus target price of $3.30, indicating a potential upside of 70.10%. Annovis Bio has a consensus target price of $17.33, indicating a potential upside of 684.31%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than ALX Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57Annovis Bio 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is ALXO or ANVS more profitable? ALX Oncology's return on equity of -115.67% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -115.67% -84.82% Annovis Bio N/A -206.01%-158.26% Which has preferable valuation & earnings, ALXO or ANVS? Annovis Bio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$134.85M-$2.20-0.88Annovis BioN/AN/A-$24.59M-$2.04-1.08 SummaryALX Oncology beats Annovis Bio on 8 of the 13 factors compared between the two stocks. Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANVS vs. The Competition Export to ExcelMetricAnnovis BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$44.23M$3.36B$6.14B$22.07BDividend YieldN/A2.29%5.66%3.58%P/E Ratio-1.0821.3485.7229.59Price / SalesN/A487.79631.4564.76Price / CashN/A47.1938.3224.53Price / Book3.3010.4313.094.61Net Income-$24.59M-$52.40M$3.30B$1.01B7 Day Performance-0.23%4.97%3.75%-0.98%1 Month Performance-3.91%17.02%10.73%2.51%1 Year Performance-72.38%34.38%85.28%14.61% Annovis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANVSAnnovis Bio2.3432 of 5 stars$2.21-2.6%$17.33+684.3%-72.6%$44.23MN/A-1.083News CoverageAnalyst ForecastGap UpHigh Trading VolumeALXOALX Oncology3.8039 of 5 stars$1.75-6.4%$3.30+88.6%+19.8%$100.14MN/A-0.8040Analyst ForecastGap UpCYBNCybinN/A$5.99+2.2%$85.00+1,319.0%N/A$150.88MN/A-1.3750CRBPCorbus Pharmaceuticals4.0831 of 5 stars$12.26+1.2%$45.43+270.5%-15.2%$148.41MN/A-2.5840Analyst ForecastBTMDbiote2.3709 of 5 stars$2.99flat$6.00+100.7%-45.6%$147.82M$199.07M3.32194News CoverageAnalyst DowngradeNKTXNkarta2.3969 of 5 stars$2.07+1.5%$13.60+557.0%-40.1%$144.89MN/A-1.40140News CoverageAnalyst ForecastSAVACassava Sciences2.8764 of 5 stars$3.14+5.0%$2.00-36.3%-83.2%$144.44MN/A-1.2330Analyst ForecastCLYMClimb Bio4.0332 of 5 stars$1.99-6.6%$9.00+352.3%N/A$144.34MN/A-2.849Analyst ForecastShort Interest ↓AVTXAvalo Therapeutics3.1947 of 5 stars$13.02+20.6%$31.67+143.2%+65.8%$142.04M$441K0.0040High Trading VolumeGLSIGreenwich LifeSciences1.0887 of 5 stars$10.16-2.3%$42.00+313.4%-13.7%$141.76MN/A-7.473CRDFCardiff Oncology2.5058 of 5 stars$2.08+1.0%$10.63+410.8%-5.6%$137.04M$680K-2.3920News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies ALX Oncology Competitors Cybin Competitors Corbus Pharmaceuticals Competitors biote Competitors Nkarta Competitors Cassava Sciences Competitors Climb Bio Competitors Avalo Therapeutics Competitors Greenwich LifeSciences Competitors Cardiff Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANVS) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredElon callingElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
